KINASE INHIBITORS
First Claim
Patent Images
1. A compound represented by the following structural formula:
- or a pharmaceutically acceptable salt thereof, wherein;
B is a monocyclic heteroaromatic ring, a 6,6 bicyclic heteroaromatic ring, or a 6,5 bicyclic heteroaromatic ring wherein B is optionally and independently substituted with R12′ and
independently optionally and independently substituted with one or more R12 groups in addition to R3, and the point of attachment to —
C(Z)- of the 6,5 bicyclic ring is on the 6 membered ring;
Z is O or S;
R1 is —
H, halogen, —
CN, —
NO2, or -T1-Q1;
T1 is absent or C1-10 aliphatic, wherein up to three methylene units of T1 are optionally and independently replaced by G wherein G is —
O—
, —
S—
, —
S(O)—
, —
S(O)2—
, —
N(R4)—
, or —
C(O)—
;
T1 is optionally and independently substituted with one or more JT1;
Q1 is absent, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Q1 is optionally and independently substituted with J1 and independently optionally and independently substituted with one or more R13 groups;
J1 is —
Y1-M1;
Y1 is absent, oxo, or C1-10 aliphatic wherein up to three methylene units of Y1 are optionally and independently replaced with G1 wherein G1 is —
N(R$)—
, —
O—
, —
S—
, —
C(O)—
, —
S(O)—
, or —
S(O)2—
, Y1 is optionally and independently substituted with one or more JT1;
M1 is C1-6 aliphatic, C3-8 cycloaliphatic, halo C1-4 aliphatic, —
O(halo C1-4 aliphatic), 3-8 membered heterocyclyl, 5-6 membered heteroaryl, phenyl, —
OR$, —
SR$, —
N(R$)2, —
C(O)R$, —
C(O)2R$, —
C(O)N(R$)2, —
OC(O)R$, —
OC(O)N(R$)2, —
NR$C(O)R$, —
NR$C(O)2R$, —
NR$C(O)N(R$)2, —
SO2N(R$)2, —
NR$S(O)2R$, —
S(O)R$, —
S(O)2R$, —
P(O)R$, —
P(O)2R$, —
P(O)(R$)2, or —
PO(OR$)2;
M1 is optionally and independently substituted with one or more J;
or M1 is absent, halogen, —
N(O)2, or —
CN;
R2 is —
H, halogen, —
CN, —
N(O)2, or optionally and independently substituted C1-C6 alkyl;
R3 is halogen, —
CN, —
NO2, or -T2-Q2;
T2 is absent or C1-10 aliphatic, wherein up to three methylene units of T2 are optionally and independently replaced by G′
wherein G′
is —
O—
, —
S—
, —
S(O)—
, —
S(O)2—
, —
N(R4)—
, or —
C(O)—
;
T2 is optionally and independently substituted with one or more JT2;
Q2 is absent, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Q2 is optionally and independently substituted with J2 and independently optionally and independently substituted with one or more R13 groups;
wherein when R1 and R2 are —
H, R12 is absent, R12 is absent, Z is O, R3 is -T2-Q2 then -T2-Q2 is not absent, —
NHCH2CH(OH)CH2OH, or J2 is —
Y2-M2;
Y2 is absent, oxo, or C1-10 aliphatic, wherein up to three methylene units of Y2 are optionally and independently replaced with G1′
wherein G1′
is —
N(R$)—
, —
O—
, —
S—
, —
C(O)—
, —
S(O)—
, or —
S(O)2—
, Y2 is optionally and independently substituted with one or more JT2;
M2 is C1-6 aliphatic, C3-8 cycloaliphatic, halo C1-4 aliphatic, —
O(halo C1-4 aliphatic), 3-8 membered heterocyclyl, heteroaryl, aryl, —
OR$, —
SR$, —
N(R$)2, —
C(O)R$, —
C(O)2R$, —
C(O)N(R$)2, —
OC(O)R$, —
OC(O)N(R$)2, —
NR$C(O)R$, —
NR$C(O)2R$, —
NR$C(O)N(R$)2, —
SO2N(R$)2, —
NR$S(O)2R$, —
S(O)R$, —
S(O)2R$, —
P(O)R$, —
P(O)2R$, —
P(O)(R$)2, or —
PO(OR$)2;
wherein M2 is optionally and independently substituted with one or more J;
or M2 is absent, halogen, —
N(O)2, or —
CN;
each J is independently halogen, C1-6 aliphatic, C3-6 cycloaliphatic, —
NO2, —
CN, —
N(R$)2, —
OR$, —
C(O)R$, —
C(O)N(R$)2, —
C(O)2R$, oxo, —
O(haloC1-4 aliphatic), or halo C1-4 aliphatic;
R4 is —
H or an optionally and independently substituted C1-C6 alkyl;
each JT1 is independently halogen, —
CN, —
N(O)2, or hydroxy;
each JT2 is independently halogen, —
CN, —
N(O)2, or hydroxy;
each R$ is independently —
H or C1-C6 alkyl;
each R12 is independently halogen, amino, aminoalkyl, alkylaminoalkyl, alkoxy, hydroxy, —
CN, —
NO2, or optionally and independently substituted C1-C6 alkyl;
each R12′
is independently halogen, amino, aminoalkyl, alkylaminoalkyl, alkoxy, hydroxy, —
CN, —
NO2, or optionally and independently substituted C1-C10 aliphatic wherein up to three methylene units are optionally and independently replaced by G′
wherein G′
is —
O—
, —
S(O)p—
, —
N(R4)—
, or —
C(O)—
, and each methylene unit is optionally and independently substituted with one or more JT3;
or each R12 is cycloaliphatic, phenyl, heteroaryl, each independently and optionally substituted with one or more JT4;
each JT3 is independently halogen, —
CN, —
NO2, cycloaliphatic, or phenyl;
each JT4 is independently halogen, C1-C6 alkyl, or C1-C6 alkoxy;
each R13 is independently halogen, amino, aminoalkyl, alkylaminoalkyl, alkoxy, hydroxy, —
CN, —
NO2, oxo or optionally and independently substituted C1-C6 alkyl; and
p is 0, 1 or 2;
with the proviso the compound is not (2-amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)(6-aminopyridin-3-yl)methanone, (2-amino-5-bromopyridin-3-yl)(6-(2-methoxyethylamino)pyridin-3-yl)methanone, (2-amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)(6-(2-methoxyethylamino)pyridin-3-yl)methanone, (2-amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)(6-(isobutylamino)pyridin-3-yl)methanone, (2-amino-5-bromopyridin-3-yl)(6-fluoropyridin-3-yl)methanone, methanone (2-amino-5-chloro-3-pyridinyl)-4-pyridinyl-, benzenesulfonamide, N-[2-[(2-amino-3pyridinyl)carbonyl]-5-chloro-3-pyridinyl]-4-chloro-(trifluoromethyl) or methanone, (2-amino-5-chloro-3-pyridinyl)-4-pyridinyl-.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
64 Citations
101 Claims
-
1. A compound represented by the following structural formula:
-
or a pharmaceutically acceptable salt thereof, wherein; B is a monocyclic heteroaromatic ring, a 6,6 bicyclic heteroaromatic ring, or a 6,5 bicyclic heteroaromatic ring wherein B is optionally and independently substituted with R12′ and
independently optionally and independently substituted with one or more R12 groups in addition to R3, and the point of attachment to —
C(Z)- of the 6,5 bicyclic ring is on the 6 membered ring;Z is O or S; R1 is —
H, halogen, —
CN, —
NO2, or -T1-Q1;T1 is absent or C1-10 aliphatic, wherein up to three methylene units of T1 are optionally and independently replaced by G wherein G is —
O—
, —
S—
, —
S(O)—
, —
S(O)2—
, —
N(R4)—
, or —
C(O)—
;
T1 is optionally and independently substituted with one or more JT1;Q1 is absent, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Q1 is optionally and independently substituted with J1 and independently optionally and independently substituted with one or more R13 groups; J1 is —
Y1-M1;Y1 is absent, oxo, or C1-10 aliphatic wherein up to three methylene units of Y1 are optionally and independently replaced with G1 wherein G1 is —
N(R$)—
, —
O—
, —
S—
, —
C(O)—
, —
S(O)—
, or —
S(O)2—
, Y1 is optionally and independently substituted with one or more JT1;M1 is C1-6 aliphatic, C3-8 cycloaliphatic, halo C1-4 aliphatic, —
O(halo C1-4 aliphatic), 3-8 membered heterocyclyl, 5-6 membered heteroaryl, phenyl, —
OR$, —
SR$, —
N(R$)2, —
C(O)R$, —
C(O)2R$, —
C(O)N(R$)2, —
OC(O)R$, —
OC(O)N(R$)2, —
NR$C(O)R$, —
NR$C(O)2R$, —
NR$C(O)N(R$)2, —
SO2N(R$)2, —
NR$S(O)2R$, —
S(O)R$, —
S(O)2R$, —
P(O)R$, —
P(O)2R$, —
P(O)(R$)2, or —
PO(OR$)2;
M1 is optionally and independently substituted with one or more J;
or M1 is absent, halogen, —
N(O)2, or —
CN;R2 is —
H, halogen, —
CN, —
N(O)2, or optionally and independently substituted C1-C6 alkyl;R3 is halogen, —
CN, —
NO2, or -T2-Q2;T2 is absent or C1-10 aliphatic, wherein up to three methylene units of T2 are optionally and independently replaced by G′
wherein G′
is —
O—
, —
S—
, —
S(O)—
, —
S(O)2—
, —
N(R4)—
, or —
C(O)—
;
T2 is optionally and independently substituted with one or more JT2;Q2 is absent, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Q2 is optionally and independently substituted with J2 and independently optionally and independently substituted with one or more R13 groups;
wherein when R1 and R2 are —
H, R12 is absent, R12 is absent, Z is O, R3 is -T2-Q2 then -T2-Q2 is not absent, —
NHCH2CH(OH)CH2OH, orJ2 is —
Y2-M2;Y2 is absent, oxo, or C1-10 aliphatic, wherein up to three methylene units of Y2 are optionally and independently replaced with G1′
wherein G1′
is —
N(R$)—
, —
O—
, —
S—
, —
C(O)—
, —
S(O)—
, or —
S(O)2—
, Y2 is optionally and independently substituted with one or more JT2;M2 is C1-6 aliphatic, C3-8 cycloaliphatic, halo C1-4 aliphatic, —
O(halo C1-4 aliphatic), 3-8 membered heterocyclyl, heteroaryl, aryl, —
OR$, —
SR$, —
N(R$)2, —
C(O)R$, —
C(O)2R$, —
C(O)N(R$)2, —
OC(O)R$, —
OC(O)N(R$)2, —
NR$C(O)R$, —
NR$C(O)2R$, —
NR$C(O)N(R$)2, —
SO2N(R$)2, —
NR$S(O)2R$, —
S(O)R$, —
S(O)2R$, —
P(O)R$, —
P(O)2R$, —
P(O)(R$)2, or —
PO(OR$)2;
wherein M2 is optionally and independently substituted with one or more J;
or M2 is absent, halogen, —
N(O)2, or —
CN;each J is independently halogen, C1-6 aliphatic, C3-6 cycloaliphatic, —
NO2, —
CN, —
N(R$)2, —
OR$, —
C(O)R$, —
C(O)N(R$)2, —
C(O)2R$, oxo, —
O(haloC1-4 aliphatic), or halo C1-4 aliphatic;R4 is —
H or an optionally and independently substituted C1-C6 alkyl;each JT1 is independently halogen, —
CN, —
N(O)2, or hydroxy;each JT2 is independently halogen, —
CN, —
N(O)2, or hydroxy;each R$ is independently —
H or C1-C6 alkyl;each R12 is independently halogen, amino, aminoalkyl, alkylaminoalkyl, alkoxy, hydroxy, —
CN, —
NO2, or optionally and independently substituted C1-C6 alkyl;each R12′
is independently halogen, amino, aminoalkyl, alkylaminoalkyl, alkoxy, hydroxy, —
CN, —
NO2, or optionally and independently substituted C1-C10 aliphatic wherein up to three methylene units are optionally and independently replaced by G′
wherein G′
is —
O—
, —
S(O)p—
, —
N(R4)—
, or —
C(O)—
, and each methylene unit is optionally and independently substituted with one or more JT3;
or each R12 is cycloaliphatic, phenyl, heteroaryl, each independently and optionally substituted with one or more JT4;each JT3 is independently halogen, —
CN, —
NO2, cycloaliphatic, or phenyl;each JT4 is independently halogen, C1-C6 alkyl, or C1-C6 alkoxy; each R13 is independently halogen, amino, aminoalkyl, alkylaminoalkyl, alkoxy, hydroxy, —
CN, —
NO2, oxo or optionally and independently substituted C1-C6 alkyl; andp is 0, 1 or 2; with the proviso the compound is not (2-amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)(6-aminopyridin-3-yl)methanone, (2-amino-5-bromopyridin-3-yl)(6-(2-methoxyethylamino)pyridin-3-yl)methanone, (2-amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)(6-(2-methoxyethylamino)pyridin-3-yl)methanone, (2-amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)(6-(isobutylamino)pyridin-3-yl)methanone, (2-amino-5-bromopyridin-3-yl)(6-fluoropyridin-3-yl)methanone, methanone (2-amino-5-chloro-3-pyridinyl)-4-pyridinyl-, benzenesulfonamide, N-[2-[(2-amino-3pyridinyl)carbonyl]-5-chloro-3-pyridinyl]-4-chloro-(trifluoromethyl) or methanone, (2-amino-5-chloro-3-pyridinyl)-4-pyridinyl-. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 22, 23, 24, 26, 27, 28, 38, 47, 57, 66, 75, 85, 86, 87, 88, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)
s is 0, 1 or 2; u is 0 or 1; X is, —
O—
, —
S—
, or —
NRx—
; andRx is absent or —
H.
-
-
12. The compound of claim 11 wherein ring B is represented by the following structural formula:
-
13. The compound of claim 12 wherein ring B is pyridyl substituted with R3 and independently optionally and independently substituted with R12′
- and independently and optionally substituted with R12.
-
14. The compound of claim 13 wherein:
-
R3 is -T2-Q2; T2 is absent or C1-10 aliphatic, wherein up to three methylene units of T2 are optionally and independently replaced by G′
wherein G′
is —
O—
, —
S—
, —
N(R4)—
, or —
C(O)—
;
T2 is optionally and independently substituted with one or more JT2;J2 is —
Y2-M2;Y2 is absent, oxo, or C1-10 aliphatic wherein up to three methylene units of Y2 are independently and optionally replaced with G1′
wherein G1′
is —
N(R$)—
, —
O—
, —
C(O)—
, or —
S(O)2—
, Y2 is optionally and independently substituted with one or more JT2;M2 is C1-6 aliphatic, C3-8 cycloaliphatic, 3-8 membered heterocyclyl, 5-12 membered heteroaryl, 5-12 membered aryl, —
N(R$)2, —
OR$, —
C(O)R$, —
C(O)2R$, —
S(O)R$, or —
S(O)2R$ wherein M2 is optionally and independently substituted with one or more J;
or M2 is absent, —
NO2, or —
CN; andeach J is independently halogen, C1-6 aliphatic, —
NO2, —
CN, N(R$)2, —
OR$, —
COR$, —
CON(R$)2, —
CO2R$, oxo or halo C1-4 aliphatic.
-
-
15. The compound of claim 14 wherein:
-
T2 is absent or C1-10 aliphatic, wherein up to three methylene units of T2 are optionally and independently replaced by G′
wherein G′
is —
N(R4)—
, —
O—
, —
S—
, or —
C(O)—
;
T2 is optionally and independently substituted with one or more JT2;Y2 is absent, oxo, or C1-10 aliphatic wherein up to three methylene units of Y2 are optionally and independently replaced with G1′
wherein G1′
is —
O—
, —
N(R$)—
, —
C(O)—
, or —
SO2—
, Y2 is optionally and independently substituted with one or more JT2;M2 is —
OR$, —
N(R$)2, —
C(O)R$, —
C(O)2R$, —
S(O)R$, or —
S(O)2R$, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, imidazolyl, pyrazolyl, furyl, tetrahydrofuryl, thienyl, tetrahydrothienyl, pyranyl, tetrahydropyranyl, isooxazolyl, piperidinyl, pyrrolidinyl, cyclopentyl, cyclohexyl, cyclopropyl, naphthyl, or phenyl, wherein M2 is optionally and independently substituted with one or more J;
or M2 is absent, —
N(O)2, or —
CN; andeach J is independently halogen, C1-6 aliphatic, —
NO2, —
CN, —
N(R$)2, —
OR$, oxo, or halo C1-4 aliphatic.
-
-
16. The compound of claim 15 wherein:
Q2 is selected from the group consisting of absent, cyclopropyl, cyclopentyl, cyclobutyl, cyclohexyl, cyclohexenyl, phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, imidazolyl, pyrazolyl, oxazalolyl, oxadiazolyl, thiazolyl, thiadiazolyl, piperidinyl, piperizinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, azepanyl, diazepanyl, triazepanyl, azocanyl, diazocanyl, triazocanyl, indolyl, indazolyl, benzimidazolyl, quinolyl, quinoxalyl, indolinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, oxazocanyl, oxazepanyl, azabicyclopentyl, azabicyclohexyl, azabicycloheptyl, azabicyclooctyl, azabicyclononyl, azabicyclodecyl, diazabicyclohexyl, diazabicycloheptyl, azetidinyl, isoindolinyl, isoindolyl, dihydroindazolyl, dihydrobenzimidazolyl, morpholinyl, tetrahydropyridyl, dihydropyridyl, tetrahydropyrazinyl, dihydropyrazinyl, tetrahydropyrimidinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydropyrazolyl, dihydroimidazolyl, octahydropyrrolopyrazyl, octahydropyrrolopyridyl, octahydropyridopyrazyl, octahydropyridopyridyl, diazabicyclooctyl, diazabicyclononyl, diazabicyclodecyl, thiazepanyl, and thiazocanyl wherein each ring is independently optionally and independently substituted with J2 and independently and optionally substituted with one or more R13 groups.
-
17. The compound of claim 16, wherein:
Q2 is selected from the group consisting of absent, cyclohexyl, diazabicyclooctyl, phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, imidazolyl, pyrazolyl, oxazalolyl, oxadiazolyl, thiazolyl, azetidinyl, morpholinyl, azepanyl, diazabicycloheptyl, diazabicyclooctyl, indolyl, tetrahydropyridyl, dihydropyridyl, octahydropyrrolopyrazyl, octahydropyrrolopyridyl, octahydropyridopyrazyl, octahydropyridopyridyl, thiadiazolyl, piperidinyl, piperazinyl, pyrrolidinyl, diazepanyl, and oxazepanyl wherein each ring is independently optionally and independently substituted with J2 and independently and optionally substituted with one or more R13 groups.
-
18. The compound of claim 17 wherein:
Q2 is selected from the group consisting of absent, cyclohexyl, 3,8-diazabicyclo[3.2.1.]octane, phenyl, pyridyl, piperidinyl, piperazinyl, diazepanyl, pyrrolidinyl, pyrrolyl, pyrrazolyl, azetidinyl, morpholinyl, azepanyl, 2,5 diazabicycloheptyl, diazabicyclooctyl, indolyl, tetrahydropyridyl, octahydro-1H-pyrrolo[2,3-b]pyrazyl, octahydropyrrolo[1,2-a]pyrazyl, and oxazepanyl wherein each ring is independently optionally and independently substituted with J2 and independently and optionally substituted with one or more R13 groups.
-
22. The compound of claim 18 wherein Q2 is represented by the following structural formula:
t is 0 or 1; and q is 0 or 1.
-
23. The compound of claim 22 wherein the compound is represented by a structural formula selected from the group consisting of:
-
24. The compound of claim 10 wherein ring B is imidazolyl substituted with R3 and independently optionally and independently substituted with R12.
-
26. The compound of claim 11 wherein X is —
- S—
.
- S—
-
27. The compound of claim 26 ring B is thiazolyl, thiadiazolyl or thienyl wherein ring B is substituted with R3 and independently optionally and independently substituted with R12.
-
28. The compound of claim 27 ring B is thiazolyl substituted with R3 and independently optionally and independently substituted with R12.
-
38. The compound of claim 27 ring B is thiadiazolyl substituted with R3.
-
47. The compound of claim 27 ring B is thienyl substituted with R3 and independently optionally and independently substituted with R12.
-
57. The compound of claim 12 wherein ring B is pyrimidinyl substituted with R3 and independently optionally and independently substituted with R12′
- and independently optionally substituted with R12.
-
66. The compound of claim 12 wherein ring B is pyrazinyl substituted with R3 and independently optionally and independently substituted with R12′
- and independently optionally substituted with R12.
-
75. The compound of claim 11 wherein ring B is thiazolyl substituted with R3 and independently optionally and independently substituted with R12.
-
85. The compound of claim 18 wherein Q2 is represented by a structural formula represented by:
t is 0 or 1; and q′
is 0, 1 or 2.
-
86. The compound of claim 85 wherein the compound is represented by a structural formula selected from the group consisting of:
-
87. The compound of claim 85 wherein Q2 is represented by a structural formula represented by:
t is 0 or 1; and q′
is 1 or 2.
-
88. The compound of claim 87 wherein the compound is represented by a structural formula selected from the group consisting of:
-
91. The compound of claim 15 wherein:
Q2 is absent.
-
92. The compound of claim 91 wherein:
T2 is C1-10 aliphatic, wherein two methylene units of T1 are independently replaced by G′
wherein G′
is —
N(R4)—
, —
O—
, —
S—
, or —
C(O)—
;
T1 is optionally and independently substituted with one or more JT2.
-
93. The compound of claim 92 wherein:
T2 is C1-10 aliphatic, wherein two methylene units of T1 are independently replaced by G′
wherein G′
is —
N(R4)—
, —
O—
, or —
S—
;
T1 is optionally and independently substituted with one or more JT2.
-
94. The compound of claim 93 wherein:
T2 is C1-10 aliphatic, wherein two methylene units of T1 are replaced by G′
wherein G′
is —
N(R4)—
;
T1 is optionally and independently substituted with one or more JT2.
-
95. The compound of claim 94, wherein the compound is represented by a structural formula selected from the group consisting of:
-
96. A composition comprising a compound of pharmaceutically acceptable salt thereof according to claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
-
97. A method of treating or preventing a protein kinase-mediated condition in a subject, comprising administering to the subject an effective amount of a compound or pharmaceutically acceptable salt thereof or composition of claim 1.
-
98. The method of claim 97, wherein the protein kinase-mediated condition is a GSK 3 mediated condition.
-
99. The method of claim 98, wherein the GSK 3 mediated condition is selected from the group consisting of diabetes, Alzheimer'"'"'s disease, Huntington'"'"'s disease, Parkinson'"'"'s disease, AIDS-associated dementia, bipolar disorder, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, leukocytopenia, cardiomyocyte hypertrophy, stroke, and rheumatoid arthritis.
-
100. The method of claim 97, wherein the protein kinase-mediated condition is a PKCtheta mediated condition.
-
101. The method of claim 100, wherein the PKCtheta mediated condition is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, irritable bowel disease, T cell leukaemias and lymphomas.
-
19-21. -21. (canceled)
-
25. (canceled)
-
29-37. -37. (canceled)
-
39-46. -46. (canceled)
-
48-56. -56. (canceled)
-
58-65. -65. (canceled)
-
67-74. -74. (canceled)
-
76-84. -84. (canceled)
-
89-90. -90. (canceled)
Specification